Comparison of Anticoagulants for Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Pilot Study
| Autor: | Maari L Loy, Andrew B. Brown, Todd W Chapin, Mitchell G Sand, Cornelius M. Dyke, David D. Leedahl, Andrew M Pasek |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Bypass grafting Pyridones Cost-Benefit Analysis Administration Oral Pilot Projects 030204 cardiovascular system & hematology Drug Costs 03 medical and health sciences 0302 clinical medicine Internal medicine Atrial Fibrillation medicine Humans Pharmacology (medical) In patient Prospective Studies 030212 general & internal medicine Coronary Artery Bypass Aged Pharmacology business.industry Anticoagulants Atrial fibrillation Middle Aged medicine.disease Cardiac surgery Treatment Outcome medicine.anatomical_structure North Dakota Cardiology Pyrazoles Female Warfarin Drug Monitoring Cardiology and Cardiovascular Medicine business Factor Xa Inhibitors Artery |
| Zdroj: | Journal of Cardiovascular Pharmacology and Therapeutics. 25:523-530 |
| ISSN: | 1940-4034 1074-2484 |
| DOI: | 10.1177/1074248420929483 |
| Popis: | Background: Direct-acting oral anticoagulants are indicated for the treatment of nonvalvular atrial fibrillation, but their use in patients after undergoing cardiac surgery is poorly defined despite a high prevalence of postoperative atrial fibrillation in this population. Methods: Patients diagnosed with postoperative atrial fibrillation were prospectively randomized to warfarin or apixaban. Safety, efficacy, and economic outcomes were evaluated until their 4- to 6-week postoperative appointment. Results: While this pilot study was not powered to determine a difference in safety or efficacy, adverse event rates were similar to the published literature. It was noted that a patient’s course of therapy when utilizing apixaban was significantly less costly than warfarin when including medication, bridging, and laboratory expenses. Conclusion: Apixaban and warfarin both appeared to be safe and effective for anticoagulation throughout the duration of this pilot study in treating postoperative atrial fibrillation after coronary artery bypass grafting. Apixaban was associated with significantly less expense when bridging and monitoring costs were included in addition to medication expense. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|